Adam Zimet

Adam Zimet serves as a procurement professional specializing in research and development acquisitions within the federal government, with a focused mandate on advancing scientific and technical innovation. He manages the full lifecycle of complex contract actions related to physical, engineering, and life sciences R&D, ensuring alignment with federal research priorities and regulatory compliance. His work supports mission-critical initiatives requiring advanced analytical capabilities, laboratory instrumentation, and technical services from specialized vendors, positioning him as a key conduit between federal science objectives and industry execution. Zimet’s contracting patterns reflect a preference for open competition, with no set-asides utilized in his portfolio, indicating a focus on technical merit and capability over socioeconomic categorization. He engages with a broad spectrum of vendors, including large research institutions, specialized engineering firms, and niche technology providers capable of delivering high-complexity R&D solutions. His working relationships are characterized by rigorous evaluation of technical proposals, adherence to FAR and agency-specific acquisition guidelines, and an emphasis on performance-based contract structures that incentivize innovation and measurable outcomes. His procurement activity is exclusively concentrated under NAICS 541712, reflecting a deep specialization in research and development across the physical, engineering, and life sciences. This includes the acquisition of experimental design services, computational modeling, analytical instrumentation, clinical trial support, and advanced materials testing. His domain expertise spans disciplines such as chemical engineering, biomedical instrumentation, environmental science, and applied physics, requiring a nuanced understanding of scientific methodologies and technical specifications. Zimet’s approach underscores a commitment to technical excellence and mission-driven outcomes, prioritizing vendor capability and scientific rigor over socioeconomic preferences. His contracting strategy ensures that federal R&D investments are directed toward the most qualified and capable performers, fostering innovation through competitive, performance-based acquisitions.